NYC-based FCB Health appointed Kim Barke to the role of group creative director to lead its oncology accounts.
Being born at below-normal weight is associated with a lower intelligence quotient (IQ) not only in childhood and young adulthood, but even at age 50, according to a new study from Denmark.
Remedy Pharmaceuticals announced that Biogen completed an asset purchase of its Phase 3 candidate, Cirara.
India’s drug pricing regulator has demanded explanations from 65 domestic and global drugmakers for selling new forms of essential diabetes and antibiotic drugs without its approval.
More than a dozen Democratic attorneys general sought to intervene to defend a key part of the Obamacare healthcare law – subsidy payments to insurance companies – which is under threat in a court case.
Rockville, Mary.-based GlycoMimetics’ shares jumped dramatically on the news of positive interim Phase II data for GMI-1271 for acute myeloid leukemia.
As Teva Pharmaceutical narrows down its candidate for a new chief executive officer, the company is shuttering a plant in Hungary and laying off 500 employees, according to reports.
Shire’s 2015 bet on Dyax and its experimental drug to treat the rare illness, hereditary angioedema (HAE), is paying off. The company revealed stellar Phase III data for lanadelumab that could transform the way HAE patients are treated.
FDA Approves Kalydeco for More Than 900 People Ages 2 and Older with Cystic Fibrosis Who Have Certain Residual Function Mutations
Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration approved Kalydeco (ivacaftor) for use in people with cystic fibrosis ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.